
Opinion|Videos|December 19, 2025
ASCENT-03 and ASCENT-04 Sacituzumab Govitecan Safety Data Shared at SABCS 2025
Author(s)Laura Huppert, MD
Advertisement
Updated safety from the ASCENT-03 and ASCENT-04 trials were shared at the 2025 San Antonio Breast Cancer Symposium (SABCS). Both studies explored sacituzumab govitecan in the first-line setting for patients with triple-negative breast cancer, with ASCENT-03 exploring the ADC as a monotherapy and ASCENT-04 evaluating the ADC in combination with the PD-1 inhibitor pembrolizumab. In this video, Laura Huppert, MD, highlights the safety outcomes from the trials presented at SABCS 2025 and shares her expertise on managing adverse events associated with these treatments.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer
5










































